Global Cancer Immunotherapy Market Size, Growth, Opportunity and Forecast

  • Product Code:
    RP-ID-10008431
  • Published Date:
    24 Feb 2020
  • Region:
    Global
  • Pages:
    138
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-12

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

The global Cancer Immunotherapymarket was valued at USD 61.88billion in 2016 and is projected to reach USD 200.44billionby 2025, growing at a CAGR of 13.95% from 2017 to 2025.
Immunotherapy is treatment that uses certain parts of a person's immune system to fight diseases. Cancer is prevalent all over the globe causing the demand of efficient treatment methods to increase. The market is expected to grow at a high rate.

Sample Infographics:



Market Dynamics:
1. Market Drivers
1.1 Rise in Incidence of Cancer
1.2 Increase in Adoption of Immunotherapy
1.3 Development of Bioinformatics Tools
2. Market Restraints
2.1 Cost Constraints

Market Segmentation:
1. By End User:
1.1 Hospitals
1.2 Clinics & Others

2. By Application:
2.1 Lung Cancer
2.2 Breast Cancer
2.3 Multiple Myeloma
2.4 Colorectal Cancer
2.5 Head & Neck Cancer
2.6 Prostate Cancer
2.7 Melanoma
2.8 Other Cancer Types

3. By Product Type:
3.1 Monoclonal Antibodies
3.1.1 Naked Monoclonal Antibodies
3.1.2 Conjugated Monoclonal Antibodies
3.1.3 Bispecific Monoclonal Antibodies
3.2 Vaccines
3.2.1 Prophylactic Vaccines
3.2.2 Therapeutic Vaccines
3.3 Checkpoint Inhibitors
3.3.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
3.3.2 Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
3.4 Cell Therapies
3.4.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
3.4.2 Dendritic Cells
3.5 Immuno modulators
3.5.1 Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf& G-Csf)
3.5.2 Interferons (IFN)
3.5.3 Interleukins (IL)
3.5.4 Oncolytic Virus

4. By Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa

Competitive Landscape:
The major players in the market are as follows:
1. Amgen Inc.
2. Astrazeneca
3. Bayer AG
4. Bristol-Myers Squibb
5. ELI Lilly and Company
6. Janssen Global Services, LLC (Johnson and Johnson)
7. Merck
8. Novartis
9. Pfizer
10. F. Hoffmann-La Roche Ltd
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Cancer Immunotherapymarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL CANCER IMMUNOTHERAPYMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CANCER IMMUNOTHERAPYMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER:
5.1 Hospitals
5.2 Clinics & Others

6 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION:
6.1 Lung Cancer
6.2 breast cancer
6.3 Multiple Myeloma
6.4 Colorectal Cancer
6.5 Head & Neck Cancer
6.6 Prostate Cancer
6.7 Melanoma
6.8 Other Cancer Types

7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE:
7.1 Monoclonal Antibodies
7.1.1 Naked Monoclonal Antibodies
7.1.2 Conjugated Monoclonal Antibodies
7.1.3 Bispecific Monoclonal Antibodies
7.2 Vaccines
7.2.1 Prophylactic Vaccines
7.2.2 Therapeutic Vaccines
7.3 Checkpoint Inhibitors
7.3.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.3.2 Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
7.4 Cell Therapies
7.4.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.4.2 Dendritic Cells
7.5 Immuno modulators
7.5.1 Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf& G-Csf)
7.5.2 Interferons (IFN)
7.5.3 Interleukins (IL)
7.5.4 Oncolytic Virus

8 GLOBAL CANCER IMMUNOTHERAPYMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 – 2025

9 GLOBAL CANCER IMMUNOTHERAPYMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Amgen Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Astrazeneca
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Bayer AG
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Bristol-Myers Squibb
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 ELI Lilly and Company
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Janssen Global Services, LLC (Johnson and Johnson)
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Merck
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Novartis
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Pfizer
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 F. Hoffmann-La Roche Ltd
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

11 Appendix
11.1 Related Reports
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
1. Amgen Inc.
2. Astrazeneca
3. Bayer AG
4. Bristol-Myers Squibb
5. ELI Lilly and Company
6. Janssen Global Services, LLC (Johnson and Johnson)
7. Merck
8. Novartis
9. Pfizer
10. F. Hoffmann-La Roche Ltd
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports